Escherichia coli ST131: The Quintessential Example of anInternational Multiresistant High-Risk Clone

Advances in Applied Microbiology

Volumn 90, Issue , 2015, Pages 109-154

  Mathers, Amy J ^a   Peirano, Gisele ^b,c   Pitout, Johann D D ^b,c  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

Antimicrobial resistance; Escherichia coli; ExPEC; High risk clone; Sequence type 131

Indexed keywords

EXTENDED SPECTRUM BETA LACTAMASE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENOME; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; BACTERIUM DETECTION; CLONE; COST EFFECTIVENESS ANALYSIS; ESCHERICHIA COLI; GENE SEQUENCE; HOST PATHOGEN INTERACTION; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MULTILOCUS SEQUENCE TYPING; NONHUMAN; PHYLOGENY; POLYMERASE CHAIN REACTION; PULSED FIELD GEL ELECTROPHORESIS; RISK FACTOR; ANIMAL; CLASSIFICATION; DRUG EFFECTS; ESCHERICHIA COLI INFECTIONS; GENETICS; HUMAN; INTERNATIONAL COOPERATION; ISOLATION AND PURIFICATION; MICROBIOLOGY; MULTIDRUG RESISTANCE; TRANSMISSION;

ESCHERICHIA COLI;

ANIMALS; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HUMANS; INTERNATIONALITY; PHYLOGENY;

EID: 84920921364     PISSN: 00652164     EISSN: None     Source Type: Book Series    
DOI: 10.1016/bs.aambs.2014.09.002     Document Type: Article

References (150)

1. Accogli M., Giani T., Monaco M., Giufre M., Garcia-Fernandez A., Conte V., et al. Emergence of Escherichia coli ST131 sub-clone H30 producing VIM-1 and KPC-3 carbapenemases. Italy Journal of Antimicrobial Chemotherapy 2014, 69(8):2293-2296. 10.1093/jac/dku132.
2. Agabou A., Pantel A., Ouchenane Z., Lezzar N., Khemissi S., Satta D., et al. First description of OXA-48-producing Escherichia coli and the pandemic clone ST131 from patients hospitalised at a military hospital in Algeria. European Journal of Clinical Microbiology and Infectious Diseases 2014, 33(9):1641-1646. 10.1007/s10096-014-2122-y.
3. Alhashash F., Weston V., Diggle M., McNally A. Multidrug-resistant Escherichia coli bacteremia. Emerging Infectious Diseases 2013, 19(10):1699-1701. 10.3201/eid1910.130309.
4. Alvarez M., Tran J.H., Chow N., Jacoby G.A. Epidemiology of conjugative plasmid-mediated AmpC beta-lactamases in the United States. Antimicrobial Agents and Chemotherapy 2004, 48(2):533-537.
5. America I.D.S.o The 10×'20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clinical Infectious Diseases 2010, 50(8):1081-1083. 10.1086/652237.
6. Arpin C., Quentin C., Grobost F., Cambau E., Robert J., Dubois V., et al. Nationwide survey of extended-spectrum {beta}-lactamase-producing Enterobacteriaceae in the French community setting. Journal of Antimicrobial and Chemotherapy 2009, 63(6):1205-1214. dkp108 [pii]. 10.1093/jac/dkp108.
7. Banerjee R., Johnson J.R. A new clone sweeps clean: the enigmatic emergence of Escherichia coli sequence type 131. Antimicrobial Agents and Chemotherapy 2014, 58(9):4997-5004. 10.1128/AAC.02824-14.
8. Banerjee R., Johnston B., Lohse C., Chattopadhyay S., Tchesnokova V., Sokurenko E.V., et al. The clonal distribution and diversity of extraintestinal Escherichia coli isolates vary according to patient characteristics. Antimicrobial Agents and Chemotherapy 2013, 57(12):5912-5917. 10.1128/AAC.01065-13.
9. Banerjee R., Johnston B., Lohse C., Porter S.B., Clabots C., Johnson J.R. Escherichia coli sequence type 131 is a dominant, antimicrobial-resistant clonal group associated with healthcare and elderly hosts. Infection Control and Hospital Epidemiology 2013, 34(4):361-369. 10.1086/669865.
10. Banerjee R., Robicsek A., Kuskowski M.A., Porter S., Johnston B.D., Sokurenko E., et al. Molecular epidemiology of Escherichia coli sequence type 131 and its H30 and H30-Rx subclones among extended-spectrum-beta-lactamase-positive and -negative E. coli clinical isolates from the Chicago Region, 2007 to 2010. Antimicrobial Agents and Chemotherapy 2013, 57(12):6385-6388. 10.1128/AAC.01604-13.
11. Baquero F., Tedim A.P., Coque T.M. Antibiotic resistance shaping multi-level population biology of bacteria. Frontiers in Microbiology 2013, 4:15. 10.3389/fmicb.2013.00015.
12. Blanc V., Leflon-Guibout V., Blanco J., Haenni M., Madec J.Y., Rafignon G., et al. Prevalence of day-care centre children (France) with faecal CTX-M-producing Escherichia coli comprising O25b:H4 and O16:H5 ST131 strains. Journal of Antimicrobial Chemotherapy 2014, 69(5):1231-1237. 10.1093/jac/dkt519.
13. Blanco M., Alonso M.P., Nicolas-Chanoine M.H., Dahbi G., Mora A., Blanco J.E., et al. Molecular epidemiology of Escherichia coli producing extended-spectrum {beta}-lactamases in Lugo (Spain): dissemination of clone O25b:H4-ST131 producing CTX-M-15. Journal of Antimicrobial Chemotherapy 2009, 63(6):1135-1141. 10.1093/jac/dkp122.
14. Blanco J., Mora A., Mamani R., Lopez C., Blanco M., Dahbi G. Four main virotypes among extended-spectrum-beta-lactamase-producing isolates of Escherichia coli O25b:H4-B2-ST131: bacterial, epidemiological, and clinical characteristics. Journal of Clinical Microbiology 2013, 51(10):3358-3367. Spanish Group for Nosocomial, I. 10.1128/JCM.01555-13.
15. Bonnin R.A., Poirel L., Carattoli A., Nordmann P. Characterization of an IncFII plasmid encoding NDM-1 from Escherichia coli ST131. PLoS One 2012, 7(4):e34752. 10.1371/journal.pone.0034752.
16. Bryant J., Chewapreecha C., Bentley S.D. Developing insights into the mechanisms of evolution of bacterial pathogens from whole-genome sequences. Future Microbiology 2012, 7(11):1283-1296. 10.2217/fmb.12.108.
17. Buchholz U., Bernard H., Werber D., Bohmer M.M., Remschmidt C., Wilking H., et al. German outbreak of Escherichia coli O104:H4 associated with sprouts. The New England Journal of Medicine 2011, 365(19):1763-1770. 10.1056/NEJMoa1106482.
18. Bush K., Jacoby G.A. Updated functional classification of beta-lactamases. Antimicrobial Agents and Chemotherapy 2010, 54(3):969-976. 10.1128/AAC.01009-09.
19. Cagnacci S., Gualco L., Debbia E., Schito G.C., Marchese A. European emergence of ciprofloxacin-resistant Escherichia coli clonal groups O25:H4-ST 131 and O15:K52:H1 causing community-acquired uncomplicated cystitis. Journal of Clinical Microbiology 2008, 46(8):2605-2612. JCM.00640-08 [pii]. 10.1128/JCM.00640-08.
20. Cai J.C., Zhang R., Hu Y.Y., Zhou H.W., Chen G.X. Emergence of Escherichia coli sequence type 131 isolates producing KPC-2 carbapenemase in China. Antimicrobial Agents and Chemotherapy 2014, 58(2):1146-1152. 10.1128/AAC.00912-13.
21. Canton R., Coque T.M. The CTX-M beta-lactamase pandemic. Current Opinion in Microbiology 2006, 9(5):466-475. S1369-5274(06)00134-2 [pii]. 10.1016/j.mib.2006.08.011.
22. Carattoli A. Resistance plasmid families in Enterobacteriaceae. Antimicrobial Agentsand Chemotherapy 2009, 53(6):2227-2238. 10.1128/AAC.01707-08.
23. Carrer A., Poirel L., Yilmaz M., Akan O.A., Feriha C., Cuzon G., et al. Spread of OXA-48-encoding plasmid in Turkey and beyond. Antimicrob Agents Chemother 2010, 54(3):1369-1373. AAC.01312-09 [pii]. 10.1128/AAC.01312-09.
24. Castanheira M., Deshpande L.M., Mathai D., Bell J.M., Jones R.N., Mendes R.E. Early dissemination of NDM-1- and OXA-181-producing Enterobacteriaceae in Indian hospitals: report from the SENTRY Antimicrobial Surveillance Program, 2006-2007. Antimicrobial Agents and Chemotherapy 2011, 55(3):1274-1278. 10.1128/AAC.01497-10.
25. Castanheira M., Mendes R.E., Woosley L.N., Jones R.N. Trends in carbapenemase-producing Escherichia coli and Klebsiella spp. from Europe and the Americas: report from the SENTRY antimicrobial surveillance programme (2007-09). Journal of Antimicrobial Chemotherapy 2011, 66(6):1409-1411. 10.1093/jac/dkr081.
26. Chung H.C., Lai C.H., Lin J.N., Huang C.K., Liang S.H., Chen W.F., et al. Bacteremia caused by extended-spectrum-beta-lactamase-producing Escherichia coli sequence type ST131 and non-ST131 clones: comparison of demographic data, clinical features, and mortality. Antimicrobial Agents and Chemotherapy 2012, 56(2):618-622. 10.1128/AAC.05753-11.
27. Clark A.E., Kaleta E.J., Arora A., Wolk D.M. Matrix-assisted laser desorption ionization-time of flight mass spectrometry: a fundamental shift in the routine practice of clinical microbiology. Clinical Microbiology Reviews 2013, 26(3):547-603. 10.1128/CMR.00072-12.
28. Clermont O., Dhanji H., Upton M., Gibreel T., Fox A., Boyd D., et al. Rapid detection of the O25b-ST131 clone of Escherichia coli encompassing the CTX-M-15-producing strains. Journal of Antimicrobial and Chemotherapy 2009, 64(2):274-277. 10.1093/jac/dkp194.
29. Clermont O., Johnson J.R., Menard M., Denamur E. Determination of Escherichia coli O types by allele-specific polymerase chain reaction: application to the O types involved in human septicemia. Diagnostic Microbiology and Infectious Disease 2007, 57(2):129-136. 10.1016/j.diagmicrobio.2006.08.007.
30. Colpan A., Johnston B., Porter S., Clabots C., Anway R., Thao L., et al. Escherichia coli sequence type 131 (ST131) subclone H30 as an emergent multidrug-resistant pathogen among US veterans. Clinical Infectious Diseases 2013, 57(9):1256-1265. 10.1093/cid/cit503.
31. Coque T.M., Novais A., Carattoli A., Poirel L., Pitout J., Peixe L., et al. Dissemination of clonally related Escherichia coli strains expressing extended-spectrum beta-lactamase CTX-M-15. Emerging Infectious Diseases 2008, 14(2):195-200. 10.3201/eid1402.070350.
32. Cuzon G., Naas T., Bogaerts P., Glupczynski Y., Huang T.D., Nordmann P. Plasmid-encoded carbapenem-hydrolyzing beta-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium. Antimicrobial Agents and Chemotherapy 2008, 52(9):3463-3464. AAC.00543-08 [pii]. 10.1128/AAC.00543-08.
33. D'Andrea M.M., Arena F., Pallecchi L., Rossolini G.M. CTX-M-type beta-lactamases: a successful story of antibiotic resistance. International Journal of Medical Microbiology 2013, 303(6-7):305-317. 10.1016/j.ijmm.2013.02.008.
34. Deshpande P., Rodrigues C., Shetty A., Kapadia F., Hedge A., Soman R. NewDelhi Metallo-beta lactamase (NDM-1) in Enterobacteriaceae: treatment optionswith carbapenems compromised. Journal of the Association Physicians of India 2010, 58:147-149.
35. Dijkshoorn L., Ursing B.M., Ursing J.B. Strain, clone and species: comments on three basic concepts of bacteriology. Journal of Medical Microbiology 2000, 49(5):397-401.
36. Dimou V., Dhanji H., Pike R., Livermore D.M., Woodford N. Characterization of Enterobacteriaceae producing OXA-48-like carbapenemases in the UK. Journal of Antimicrobial and Chemotherapy 2012, 67(7):1660-1665. 10.1093/jac/dks124.
37. Dobrindt U. (Patho-)Genomics of Escherichia coli. International Journal of Medical Microbiology 2005, 295(6-7):357-371. 10.1016/j.ijmm.2005.07.009.
38. Doi Y., Paterson D.L. Detection of plasmid-mediated class C beta-lactamases. International Journal of Infectious Diseases 2007, 11(3):191-197. S1201-9712(06)00200-1 [pii]. 10.1016/j.ijid.2006.07.008.
39. Doumith M., Dhanji H., Ellington M.J., Hawkey P., Woodford N. Characterization of plasmids encoding extended-spectrum beta-lactamases and their addiction systems circulating among Escherichia coli clinical isolates in the UK. Journal of Antimicrobial Chemotherapy 2012, 67(4):878-885. dkr553 [pii]. 10.1093/jac/dkr553.
40. Fernández J., Montero I., Fleites A., Rodicio M.R. Cluster of Escherichia coli producing a plasmid-mediated OXA-48 beta-Lactamase in a Spanish hospital in 2012. Journal of Clinical Microbiology 2014, 52(9):3414-3417. 10.1128/JCM.01271-14.
41. Forward K.R., Willey B.M., Low D.E., McGeer A., Kapala M.A., Kapala M.M., et al. Molecular mechanisms of cefoxitin resistance in Escherichia coli from the Toronto area hospitals. Diagnostic Microbiology and Infectious Disease 2001, 41(1-2):57-63. S0732-8893(01)00278-4 [pii].
42. Foxman B. The epidemiology of urinary tract infection. Nature Reviews Urology 2010, 7(12):653-660. 10.1038/nrurol.2010.190.
43. Freeman J.T., McBride S.J., Heffernan H., Bathgate T., Pope C., Ellis-Pegler R.B. Community-onset genitourinary tract infection due to CTX-M-15-Producing Escherichia coli among travelers to the Indian subcontinent in New Zealand. Clinical Infectious Diseases 2008, 47(5):689-692. 10.1086/590941.
44. GE M. Cramming more components onto integrated circuits. Electronics 1965, 38(8):1-4.
45. Gibreel T.M., Dodgson A.R., Cheesbrough J., Fox A.J., Bolton F.J., Upton M. Population structure, virulence potential and antibiotic susceptibility of uropathogenic Escherichia coli from Northwest England. Journal of Antimicrobial Chemotherapy 2012, 67(2):346-356. dkr451 [pii]. 10.1093/jac/dkr451.
46. Gisele Peirano, Patricia A Bradford, Krystyna M Kazmierczak, Robert E Badal, Meredith Hackel, Daryl J Hoban, et al. Global Incidence of Carbapenemase-Producing Escherichia coli ST131. Emerging Infectious Diseases 2014, 20(11):1928-1931.
47. Glupczynski Y., Huang T.D., Bouchahrouf W., Rezende de Castro R., Bauraing C., Gerard M., et al. Rapid emergence and spread of OXA-48-producing carbapenem-resistant Enterobacteriaceae isolates in Belgian hospitals. International Journal of Antimicrobial Agents 2012, 39(2):168-172. S0924-8579(11)00423-7 [pii]. 10.1016/j.ijantimicag.2011.10.005.
48. Hanson N.D. AmpC beta-lactamases: what do we need to know for the future?. Journal of Antimicrobial Chemotherapy 2003, 52(1):2-4. dkg284 [pii]. 10.1093/jac/dkg284.
49. Hawser S.P., Bouchillon S.K., Hoban D.J., Badal R.E., Hsueh P.R., Paterson D.L. Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007. Antimicrobial Agents and Chemotherapy 2009, 53(8):3280-3284. AAC.00426-09 [pii]. 10.1128/AAC.00426-09.
50. Herzer P.J., Inouye S., Inouye M., Whittam T.S. Phylogenetic distribution of branched RNA-linked multicopy single-stranded DNA among natural isolates of Escherichia coli. Journal of Bacteriology 1990, 172(11):6175-6181.
51. Hilty M., Betsch B.Y., Bogli-Stuber K., Heiniger N., Stadler M., Kuffer M., et al. Transmission dynamics of extended-spectrum beta-lactamase-producing Enterobacteriaceae in the tertiary care hospital and the household setting. Clinical Infectious Diseases 2012, 55(7):967-975. 10.1093/cid/cis581.
52. Jacoby G.A. AmpC beta-lactamases. Clinical Microbiology Reviews 2009, 22(1):161-182. Table of Contents. 10.1128/CMR.00036-08.
53. Johnson J.R., Clermont O., Johnston B., Clabots C., Tchesnokova V., Sokurenko E., et al. Rapid and specific detection, molecular epidemiology, and experimental virulence of the O16 subgroup within Escherichia coli sequence type 131. Journal of Clinical Microbiology 2014, 52(5):1358-1365. 10.1128/JCM.03502-13.
54. Johnson J.R., Johnston B., Clabots C., Kuskowski M.A., Castanheira M. Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States. Clinical Infectious Diseases 2010, 51(3):286-294. 10.1086/653932.
55. Johnson J.B., Jorgensen J.H., Lewis J., Robicsek A., Menard M., Clabots C., et al. CTX-M-15-producing E. coli in the United States: predominance of sequence type ST131 (O25:H4). Paper presented at the Proceedings of the Forty-eighth Interscience Conference on antimicrobial agents and Chemotherapy, Washington 2008.
56. Johnson J.R., Menard M., Johnston B., Kuskowski M.A., Nichol K., Zhanel G.G. Epidemic clonal groups of Escherichia coli as a cause of antimicrobial-resistant urinary tract infections in Canada, 2002 to 2004. Antimicrobial Agents and Chemotherapy 2009, 53(7):2733-2739. 10.1128/AAC.00297-09.
57. Johnson J.R., Nicolas-Chanoine M.H., Debroy C., Castanheira M., Robicsek A., Hansen G., et al. Comparison of Escherichia coli ST131 pulsotypes, by epidemiologic traits, 1967-2009. Emerging Infectious Diseases 2012, 18(4):598-607. 10.3201/eid1804.111627.
58. Johnson J.R., Porter S.B., Zhanel G., Kuskowski M.A., Denamur E. Virulence of Escherichia coli clinical isolates in a murine sepsis model in relation to sequence type ST131 status, fluoroquinolone resistance, and virulence genotype. Infectious Immunity 2012, 80(4):1554-1562. 10.1128/IAI.06388-11.
59. Johnson J.R., Tchesnokova V., Johnston B., Clabots C., Roberts P.L., Billig M., et al. Abrupt emergence of a single dominant multidrug-resistant strain of Escherichia coli. Journal of Infectious Diseases 2013, 207(6):919-928. 10.1093/infdis/jis933.
60. Kumarasamy K.K., Toleman M.A., Walsh T.R., Bagaria J., Butt F., Balakrishnan R., et al. Emergence of a new antibiotic resistance in India, Pakistan and the UK: end of conventional antibiotics?. Lancet Infectious Diseases 2010, 10(9):597-602.
61. Kaper J.B., Nataro J.P., Mobley H.L. Pathogenic Escherichia coli. Nature Reviews Microbiology 2004, 2(2):123-140. 10.1038/nrmicro818.
62. Kim Y.A., Qureshi Z.A., Adams-Haduch J.M., Park Y.S., Shutt K.A., Doi Y. Features of infections due to Klebsiella pneumoniae carbapenemase-producing Escherichia coli: emergence of sequence type 131. Clinical Infectious Diseases 2012, 55(2):224-231. 10.1093/cid/cis387.
63. Koser C.U., Ellington M.J., Cartwright E.J., Gillespie S.H., Brown N.M., Farrington M., et al. Routine use of microbial whole genome sequencing in diagnostic and public health microbiology. PLoS Pathogens 2012, 8(8):e1002824. 10.1371/journal.ppat.1002824.
64. Kudinha T., Johnson J.R., Andrew S.D., Kong F., Anderson P., Gilbert G.L. Escherichia coli sequence type 131 as a prominent cause of antibiotic resistance among urinary Escherichia coli isolates from reproductive-age women. Journal of Clinical Microbiology 2013, 51(10):3270-3276. 10.1128/JCM.01315-13.
65. Lartigue M.F. Matrix-assisted laser desorption ionization time-of-flight mass spectrometry for bacterial strain characterization. Infection, Genetics, and Evolution 2013, 13:230-235. 10.1016/j.meegid.2012.10.012.
66. Lascols C., Hackel M., Marshall S.H., Hujer A.M., Bouchillon S., Badal R., et al. Increasing prevalence and dissemination of NDM-1 metallo-beta-lactamase in India: data from the SMART study (2009). Journal of Antimicrobial Chemotherapy 2011, 66(9):1992-1997. 10.1093/jac/dkr240.
67. Lau S.H., Cheesborough J., Kaufmann M.E., Woodford N., Dodgson A.R., Dodgson K.J., et al. Rapid identification of uropathogenic Escherichia coli of the O25:H4-ST131 clonal lineage using the DiversiLab repetitive sequence-based PCR system. Clinical Microbiology and Infection 2010, 16(3):232-237. 10.1111/j.1469-0691.2009.02733.x.
68. Lau S.H., Kaufmann M.E., Livermore D.M., Woodford N., Willshaw G.A., Cheasty T., et al. UK epidemic Escherichia coli strains A-E, with CTX-M-15 beta-lactamase, all belong to the international O25:H4-ST131 clone. Journal of Antimicrobial Chemotherapy 2008, 62(6):1241-1244. dkn380 [pii]. 10.1093/jac/dkn380.
69. Laupland K.B., Church D.L., Vidakovich J., Mucenski M., Pitout J.D. Community-onset extended-spectrum beta-lactamase (ESBL) producing Escherichia coli: importance of international travel. Journal of Infection 2008, 57(6):441-448. 10.1016/j.jinf.2008.09.034.
70. Lavigne J.P., Vergunst A.C., Goret L., Sotto A., Combescure C., Blanco J., et al. Virulence potential and genomic mapping of the worldwide clone Escherichia coli ST131. PLoS One 2012, 7(3):e34294. 10.1371/journal.pone.0034294.
71. Leflon-Guibout V., Blanco J., Amaqdouf K., Mora A., Guize L., Nicolas-Chanoine M.H. Absence of CTX-M enzymes but high prevalence of clones, including clone ST131, among fecal Escherichia coli isolates from healthy subjects living in the area of Paris, France. Journal of Clinical Microbiology 2008, 46(12):3900-3905. JCM.00734-08 [pii]. 10.1128/JCM.00734-08.
72. Leverstein-Van Hall M.A., Stuart J.C., Voets G.M., Versteeg D., Tersmette T., Fluit A.C. Global spread of New Delhi metallo-beta-lactamase 1. The Lancet Infectious Diseases 2010, 10(12):830-831. 10.1016/S1473-3099(10)70277-2.
73. Li Y., Li Q., Du Y., Jiang X., Tang J., Wang J., et al. Prevalence of plasmid-mediated AmpC beta-lactamases in a Chinese university hospital from 2003 to 2005: first report of CMY-2-Type AmpC beta-lactamase resistance in China. Journal of Clinical Microbiology 2008, 46(4):1317-1321. JCM.00073-07 [pii]. 10.1128/JCM.00073-07.
74. Literacka E., Bedenic B., Baraniak A., Fiett J., Tonkic M., Jajic-Bencic I., et al. blaCTX-M genes in Escherichia coli strains from Croatian hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a, blaCTX-M-15) genetic structures. Antimicrobial Agents and Chemotherapy 2009, 53(4):1630-1635. AAC.01431-08 [pii]. 10.1128/AAC.01431-08.
75. Magiorakos A.P., Srinivasan A., Carey R.B., Carmeli Y., Falagas M.E., Giske C.G., et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clinical Microbiology and Infection 2012, 18(3):268-281. 10.1111/j.1469-0691.2011.03570.x.
76. Mandell G.L., Douglas R.G., Bennett J.E., Dolin R. Mandell, Douglas, and Bennett's principles and practice of infectious diseases 2005, Churchill Livingstone, New York. 6th ed.
77. Mantengoli E., Luzzaro F., Pecile P., Cecconi D., Cavallo A., Attala L., et al. Escherichia coli ST131 producing extended-spectrum beta-lactamases plus VIM-1 carbapenemase: further narrowing of treatment options. Clinical Infectious Diseases 2011, 52(5):690-691. 10.1093/cid/ciq194.
78. Ma L., Siu L.K., Lin J.C., Wu T.L., Fung C.P., Wang J.T., et al. Updated molecular epidemiology of carbapenem-non-susceptible Escherichia coli in Taiwan: first identification of KPC-2 or NDM-1-producing E. coli in Taiwan. BMC Infectious Diseases 2013, 13:599. 10.1186/1471-2334-13-599.
79. Matsumura Y., Yamamoto M., Nagao M., Tanaka M., Machida K., Ito Y., et al. Detection of extended-spectrum-beta-lactamase-producing Escherichia coli ST131 and ST405 clonal groups by matrix-assisted laser desorption ionization-time of flight mass spectrometry. Journal of Clinical Microbiology 2014, 52(4):1034-1040. 10.1128/JCM.03196-13.
80. Mokady D., Gophna U., Ron E.Z. Virulence factors of septicemic Escherichia coli strains. Interantional Journal of Medicine Microbiology 2005, 295(6-7):455-462.
81. Moland E.S., Hanson N.D., Black J.A., Hossain A., Song W., Thomson K.S. Prevalence of newer beta-lactamases in gram-negative clinical isolates collected in the United States from 2001 to 2002. Journal of Clinical Microbiology 2006, 44(9):3318-3324. 10.1128/JCM.00756-06.
82. Morris D., Boyle F., Ludden C., Condon I., Hale J., O'Connell N., et al. Production of KPC-2 carbapenemase by an Escherichia coli clinical isolate belonging to the international ST131 clone. Antimicrobial Agents and Chemotherapy 2011, 55(10):4935-4936. 10.1128/AAC.05127-11.
83. Morris D., McGarry E., Cotter M., Passet V., Lynch M., Ludden C., et al. Detection of OXA-48 carbapenemase in the pandemic clone Escherichia coli O25b:H4-ST131 in the course of investigation of an outbreak of OXA-48-producing Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy 2012, 56(7):4030-4031. 10.1128/AAC.00638-12.
84. Mulvey M.R., Bryce E., Boyd D.A., Ofner-Agostini M., Land A.M., Simor A.E., et al. Molecular characterization of cefoxitin-resistant Escherichia coli from Canadian hospitals. Antimicrobial Agents and Chemotherapy 2005, 49(1):358-365. 10.1128/AAC.49.1.358-365.2005.
85. Naas T., Cuzon G., Gaillot O., Courcol R., Nordmann P. When carbapenem-hydrolyzing beta-lactamase Kpc meets Escherichia coli ST131 in France. Antimicrobial Agents and Chemotherapy 2011, 55(10):4933-4934. 10.1128/AAC.00719-11.
86. Naseer U., Haldorsen B., Tofteland S., Hegstad K., Scheutz F., Simonsen G.S., et al. Molecular characterization of CTX-M-15-producing clinical isolates of Escherichia coli reveals the spread of multidrug-resistant ST131 (O25:H4) and ST964 (O102:H6) strains in Norway. APMIS 2009, 117(7):526-536. APM2465 [pii]. 10.1111/j.1600-0463.2009.02465.x.
87. Nataro J.P., Kaper J.B. Diarrheagenic Escherichia coli. Clinical Microbiology Reviews 1998, 11(1):142-201.
88. Nicolas-Chanoine M.H., Bertrand X., Madec J.Y. Escherichia coli ST131, an intriguing clonal group. Clinical Microbiology Reviews 2014, 27(3):543-574. 10.1128/CMR.00125-13.
89. Nicolas-Chanoine M.H., Blanco J., Leflon-Guibout V., Demarty R., Alonso M.P., Canica M.M., et al. Intercontinental emergence of Escherichia coli clone O25:H4-ST131 producing CTX-M-15. Journal of Antimicrobial Chemotherapy 2008, 61(2):273-281. 10.1093/jac/dkm464.
90. Nordmann P., Naas T., Poirel L. Global spread of Carbapenemase-producing Enterobacteriaceae. Emerging Infectious Diseases 2011, 17(10):1791-1798. 10.3201/eid1710.110655.
91. Nordmann P., Poirel L. The difficult-to-control spread of carbapenemase producers in Enterobacteriaceae worldwide. Clinical Microbiology and Infection 2014, 20(9):821-830. 10.1111/1469-0691.12719.
92. Nordmann P., Poirel L., Walsh T.R., Livermore D.M. The emerging NDM carbapenemases. Trends in Microbiology 2011, 19(12):588-595. S0966-842X(11)00177-6 [pii]. 10.1016/j.tim.2011.09.005.
93. Novais A., Pires J., Ferreira H., Costa L., Montenegro C., Vuotto C., et al. Characterization of globally spread Escherichia coli ST131 isolates (1991 to 2010). Antimicrobial Agents and Chemotherapy 2012, 56(7):3973-3976. AAC.00475-12 [pii]. 10.1128/AAC.00475-12.
94. Novais A., Sousa C., de Dios Caballero J., Fernandez-Olmos A., Lopes J., Ramos H., et al. MALDI-TOF mass spectrometry as a tool for the discrimination of high-risk Escherichia coli clones from phylogenetic groups B2 (ST131) and D (ST69, ST405, ST393). European Journal of Clinical Microbiology and Infectious Diseases 2014, 33(8):1391-1399. 10.1007/s10096-014-2071-5.
95. O'Hara J.A., Hu F., Ahn C., Nelson J., Rivera J.I., Pasculle A.W., et al. Molecular epidemiology of KPC-producing Escherichia coli: Occurrence of ST131-fimH30 subclone harboring pKpQIL-like IncFIIk plasmid. Antimicrobial Agents and Chemotherapy 2014, 58(7):4234-4237. 10.1128/AAC.02182-13.
96. Organization W.H. Antimicrobial resistance a global report on Surviellence 2014, 1-257. World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland. 1st ed. L. Hiliary Cadman (Ed.).
97. Organization W.H. Antimicrobial resistance: Global report on surveillance 2014 2014, Retrieved June 2014, from World Heath Organization http://www.who.int/drugresistance/documents/surveillancereport/en/.
98. Oteo J., Diestra K., Juan C., Bautista V., Novais A., Perez-Vazquez M., et al. Extended-spectrum beta-lactamase-producing Escherichia coli in Spain belong to a large variety of multilocus sequence typing types, including ST10 complex/A, ST23 complex/A and ST131/B2. International Journal of Antimicrobial Agents 2009, 34(2):173-176. S0924-8579(09)00117-4 [pii]. 10.1016/j.ijantimicag.2009.03.006.
99. Pai H., Kang C.I., Byeon J.H., Lee K.D., Park W.B., Kim H.B., et al. Epidemiology and clinical features of bloodstream infections caused by AmpC-type-beta-lactamase-producing Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy 2004, 48(10):3720-3728. 10.1128/AAC.48.10.3720-3728.2004.
100. Pallen M.J., Loman N.J., Penn C.W. High-throughput sequencing and clinical microbiology: progress, opportunities and challenges. Current Opinion in Microbiology 2010, 13(5):625-631. S1369-5274(10)00117-7 [pii]. 10.1016/j.mib.2010.08.003.
101. Paterson D.L., Bonomo R.A. Extended-spectrum beta-lactamases: a clinical update. Clinical Microbiology Reviews 2005, 18(4):657-686. 10.1128/CMR.18.4.657-686.2005.
102. Peirano G., Pitout J.D. Molecular epidemiology of Escherichia coli producing CTX-M beta-lactamases: the worldwide emergence of clone ST131 O25:H4. International Journal of Antimicrobial Agents 2010, 35(4):316-321. 10.1016/j.ijantimicag.2009.11.003.
103. Peirano G., Pitout J.D. Fluoroquinolone-resistant Escherichia coli sequence type 131 isolates causing bloodstream infections in a canadian region with a centralized laboratory system: rapid emergence of the H30-Rx sublineage. Antimicrobial Agents and Chemotherapy 2014, 58(5):2699-2703. 10.1128/AAC.00119-14.
104. Peirano G., Schreckenberger P.C., Pitout J.D. Characteristics of NDM-1-producing Escherichia coli isolates that belong to the successful and virulent clone ST131. Antimicrobial Agents and Chemotherapy 2011, 55(6):2986-2988. 10.1128/AAC.01763-10.
105. Peirano G., van der Bij A.K., Freeman J.L., Poirel L., Nordmann P., Costello M., et al. Characteristics of Escherichia coli sequence type 131 isolates that produce extended-spectrum beta-lactamases: global distribution of the H30-Rx sublineage. Antimicrobial Agents and Chemotherapy 2014, 58(7):3762-3767. 10.1128/AAC.02428-14.
106. Peirano G., van der Bij A.K., Gregson D.B., Pitout J.D. Molecular epidemiology over an 11-year period (2000 to 2010) of extended-spectrum beta-lactamase-producing Escherichia coli causing bacteremia in a centralized Canadian region. Journal of Clinical Microbiology 2012, 50(2):294-299. 10.1128/JCM.06025-11.
107. Perry J.D., Naqvi S.H., Mirza I.A., Alizai S.A., Hussain A., Ghirardi S., et al. Prevalence of faecal carriage of Enterobacteriaceae with NDM-1 carbapenemase at military hospitals in Pakistan, and evaluation of two chromogenic media. Journal of Antimicrobial Chemotherapy 2011, 66(10):2288-2294. dkr299 [pii]. 10.1093/jac/dkr299.
108. Petty N.K., Ben Zakour N.L., Stanton-Cook M., Skippington E., Totsika M., Forde B.M., et al. Global dissemination of a multidrug resistant Escherichia coli clone. Proceedings of the National Academy of Sciences of the United States of America 2014, 111(15):5694-5699. 10.1073/pnas.1322678111.
109. Philippon A., Arlet G., Jacoby G.A. Plasmid-determined AmpC-type beta-lactamases. Antimicrobial Agents and Chemotherapy 2002, 46(1):1-11.
110. Pitout J.D. Extraintestinal pathogenic Escherichia coli: a combination of virulence with antibiotic resistance. Frontiers in Microbiology 2012, 3:9. 10.3389/fmicb.2012.00009.
111. Pitout J.D. Extraintestinal pathogenic Escherichia coli: an update on antimicrobial resistance, laboratory diagnosis and treatment. Expert Review of Anti-infective Therapy 2012, 10(10):1165-1176. 10.1586/eri.12.110.
112. Pitout J.D., Campbell L., Church D.L., Wang P.W., Guttman D.S., Gregson D.B. Using a commercial DiversiLab semiautomated repetitive sequence-based PCR typing technique for identification of Escherichia coli clone ST131 producing CTX-M-15. Journal of Clinical Microbiology 2009, 47(4):1212-1215. 10.1128/JCM.02265-08.
113. Pitout J.D., Campbell L., Church D.L., Wang P.W., Guttman D.S., Gregson D.B. Using a Commercial DiversiLabTM Semi automated repetitive sequence-based PCR typing technique for the identification of Escherichia coli clone ST131 producing CTX-M-15. Journal of Clinical Microbiology 2009, 47(4):1212-1215. JCM.02265-08 [pii]. 10.1128/JCM.02265-08.
114. Pitout J.D., Church D.L., Gregson D.B., Chow B.L., McCracken M., Mulvey M.R., et al. Molecular epidemiology of CTX-M-producing Escherichia coli in the Calgary Health Region: emergence of CTX-M-15-producing isolates. Antimicrobial Agents and Chemotherapy 2007, 51(4):1281-1286. 10.1128/AAC.01377-06.
115. Pitout J.D., Gregson D.B., Campbell L., Laupland K.B. Molecular characteristics of extended-spectrum-beta-lactamase-producing Escherichia coli isolates causing bacteremia in the Calgary Health Region from 2000 to 2007: emergence of clone ST131 as a cause of community-acquired infections. Antimicrobial Agents and Chemotherapy 2009, 53(7):2846-2851. 10.1128/AAC.00247-09.
116. Pitout J.D., Laupland K.B. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infectious Disease 2008, 8(3):159-166. 10.1016/S1473-3099(08)70041-0.
117. Platell J.L., Johnson J.R., Cobbold R.N., Trott D.J. Multidrug-resistant extraintestinal pathogenic Escherichia coli of sequence type ST131 in animals and foods. Veterinary Microbiology 2011, 153(1-2):99-108. 10.1016/j.vetmic.2011.05.007.
118. Poirel L., Bonnin R.A., Nordmann P. Genetic features of the widespread plasmid coding for the carbapenemase OXA-48. Antimicrobial Agents and Chemotherapy 2012, 56(1):559-562. AAC.05289-11 [pii]. 10.1128/AAC.05289-11.
119. Poirel L., Heritier C., Tolun V., Nordmann P. Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy 2004, 48(1):15-22.
120. Pomba C., da Fonseca J.D., Baptista B.C., Correia J.D., Martinez-Martinez L. Detection of the pandemic O25-ST131 human virulent Escherichia coli CTX-M-15-producing clone harboring the qnrB2 and aac(6')-Ib-cr genes in a dog. Antimicrobial Agents and Chemotherapy 2009, 53(1):327-328. AAC.00896-08 [pii]. 10.1128/AAC.00896-08.
121. Price L.B., Johnson J.R., Aziz M., Clabots C., Johnston B., Tchesnokova V., et al. The epidemic of extended-spectrum-beta-lactamase-producing Escherichia coli ST131 is driven by a single highly pathogenic subclone, H30-Rx. mBio 2013, 4(6):e00377-00313. 10.1128/mBio.00377-13.
122. Reuter S., Ellington M.J., Cartwright E.J., Köser C.U., Török M.E., Gouliouris T., et al. Rapid bacterial whole-genome sequencing to enhance diagnostic and public health microbiology. JAMA Internal Medicine 2013, 173(15):1397-1404. 10.1001/jamainternmed.2013.7734.
123. Riley L.W. Pandemic lineages of extraintestinal pathogenic Escherichia coli. Clinical Microbiology and Infection 2014, 20(5):380-390. 10.1111/1469-0691.12646.
124. Rodriguez-Bano J., Pascual A. Clinical significance of extended-spectrum beta-lactamases. Expert Review of Anti-infective Therapy 2008, 6(5):671-683. 10.1586/14787210.6.5.671.
125. Rooney P.J., O'Leary M.C., Loughrey A.C., McCalmont M., Smyth B., Donaghy P., et al. Nursing homes as a reservoir of extended-spectrum beta-lactamase (ESBL)-producing ciprofloxacin-resistant Escherichia coli. Journal of Antimicrobial Chemotherapy 2009, 64(3):635-641. dkp220 [pii]. 10.1093/jac/dkp220.
126. Sabat A.J., Budimir A., Nashev D., Sa-Leao R., van Dijl J., Laurent F., et al. Overview of molecular typing methods for outbreak detection and epidemiological surveillance. Eurosurveillance 2013, 18(4):20380.
127. Schwaber M.J., Navon-Venezia S., Kaye K.S., Ben-Ami R., Schwartz D., Carmeli Y. Clinical and economic impact of bacteremia with extended- spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrobial Agents and Chemotherapy 2006, 50(4):1257-1262. 50/4/1257 [pii]. 10.1128/AAC.50.4.1257-1262.2006.
128. Seema K., Ranjan Sen M., Upadhyay S., Bhattacharjee A. Dissemination of the New Delhi metallo-beta-lactamase-1 (NDM-1) among Enterobacteriaceae in a tertiary referral hospital in north India. Journal of Antimicrobial and Chemotherapy 2011, 66(7):1646-1647. dkr180 [pii]. 10.1093/jac/dkr180.
129. Shin J., Choi M.J., Ko K.S. Replicon sequence typing of IncF plasmids and the genetic environments of blaCTX-M-15 indicate multiple acquisitions of blaCTX-M-15 in Escherichia coli and Klebsiella pneumoniae isolates from South Korea. Journal of Antimicrobial Chemotherapy 2012, 67(8):1853-1857. dks143 [pii]. 10.1093/jac/dks143.
130. Spratt B.G. Exploring the concept of clonality in bacteria. Methods in Molecular Biology 2004, 266:323-352. 10.1385/1-59259-763-7:323.
131. Sullivan C.B., Diggle M.A., Clarke S.C. Multilocus sequence typing: data analysis in clinical microbiology and public health. Molecular Biotechnology 2005, 29(3):245-254. MB:29:3:245 [pii]. 10.1385/MB:29:3:245.
132. Suzuki S., Shibata N., Yamane K., Wachino J., Ito K., Arakawa Y. Change in the prevalence of extended-spectrum-beta-lactamase-producing Escherichia coli in Japan by clonal spread. Journal of Antimicrobial Chemotherapy 2009, 63(1):72-79. dkn463 [pii]. 10.1093/jac/dkn463.
133. Talbot G.H., Bradley J., Edwards J.E., Gilbert D., Scheld M., Bartlett J.G. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clinical Infectious Diseases 2006, 42(5):657-668. CID38405 [pii]. 10.1086/499819.
134. Tchesnokova V., Billig M., Chattopadhyay S., Linardopoulou E., Aprikian P., Roberts P.L., et al. Predictive diagnostics for Escherichia coli infections based on the clonal association of antimicrobial resistance and clinical outcome. Journal of Clinical Microbiology 2013, 51(9):2991-2999. 10.1128/JCM.00984-13.
135. Tenover F.C., Arbeit R.D., Goering R.V., Mickelsen P.A., Murray B.E., Persing D.H., et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. Journal of Clinical Microbiology 1995, 33(9):2233-2239.
136. Van der Bij A.K., Peirano G., Pitondo-Silva A., Pitout J.D. The presence of genes encoding for different virulence factors in clonally related Escherichia coli that produce CTX-Ms. Diagnostic Microbiology and Infectious Disease 2012, 72(4):297-302. 10.1016/j.diagmicrobio.2011.12.011.
137. van der Bij A.K., Pitout J.D. The role of international travel in the worldwide spread of multiresistant Enterobacteriaceae. Journal of Antimicrobial Chemotherapy 2012, 67(9):2090-2100. 10.1093/jac/dks214.
138. Villa L., Garcia-Fernandez A., Fortini D., Carattoli A. Replicon sequence typing of IncF plasmids carrying virulence and resistance determinants. Journal of Antimicrobial Chemotherapy 2010, 65(12):2518-2529. 10.1093/jac/dkq347.
139. Vimont S., Boyd A., Bleibtreu A., Bens M., Goujon J.M., Garry L., et al. The CTX-M-15-producing Escherichia coli clone O25b: H4-ST131 has high intestine colonization and urinary tract infection abilities. PLoS One 2012, 7(9):e46547. 10.1371/journal.pone.0046547.
140. Walsh T.R., Weeks J., Livermore D.M., Toleman M.A. Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. Lancet Infectious Diseases 2011, 11(5):355-362. 10.1016/S1473-3099(11)70059-7.
141. Weissman S.J., Johnson J.R., Tchesnokova V., Billig M., Dykhuizen D., Riddell K., et al. High-resolution two-locus clonal typing of extraintestinal pathogenic Escherichia coli. Applied Environmental Microbiology 2012, 78(5):1353-1360. 10.1128/AEM.06663-11.
142. Wiles T.J., Kulesus R.R., Mulvey M.A. Origins and virulence mechanisms of uropathogenic Escherichia coli. Experimental and Molecular Pathology 2008, 85(1):11-19. 10.1016/j.yexmp.2008.03.007.
143. Woodford N., Carattoli A., Karisik E., Underwood A., Ellington M.J., Livermore D.M. Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone. Antimicrobial Agents and Chemotherapy 2009, 53(10):4472-4482. 10.1128/AAC.00688-09.
144. Woodford N., Reddy S., Fagan E.J., Hill R.L., Hopkins K.L., Kaufmann M.E., et al. Wide geographic spread of diverse acquired AmpC beta-lactamases among Escherichia coli and Klebsiella spp. in the UK and Ireland. Journal of Antimicrobial Chemotherapy 2007, 59(1):102-105. dkl456 [pii]. 10.1093/jac/dkl456.
145. Woodford N., Turton J.F., Livermore D.M. Multiresistant Gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance. FEMS Microbiology Reviews 2011, 35(5):736-755. 10.1111/j.1574-6976.2011.00268.x.
146. Woodford N., Ward M.E., Kaufmann M.E., Turton J., Fagan E.J., James D., et al. Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum beta-lactamases in the UK. Journal of Antimicrobial Chemotherapy 2004, 54(4):735-743. 10.1093/jac/dkh424.
147. Yan J.J., Tsai L.H., Wu J.J. Emergence of the IMP-8 metallo-beta-lactamase in the Escherichia coli ST131 clone in Taiwan. Interanational Journal of Antimicrobial Agents 2012, 40(3):281-282. 10.1016/j.ijantimicag.2012.05.011.
148. Yong D., Toleman M.A., Giske C.G., Cho H.S., Sundman K., Lee K., et al. Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrobial Agents and Chemotherapy 2009, 53(12):5046-5054. AAC.00774-09 [pii]. 10.1128/AAC.00774-09.
149. Yumuk Z., Afacan G., Nicolas-Chanoine M.H., Sotto A., Lavigne J.P. Turkey: a further country concerned by community-acquired Escherichia coli clone O25-ST131 producing CTX-M-15. Journal of Antimicrobial Chemotherapy 2008, 62(2):284-288. dkn181 [pii]. 10.1093/jac/dkn181.
150. Zong Z. Complete sequence of pJIE186-2, a plasmid carrying multiple virulence factors from a sequence type 131 Escherichia coli O25 strain. Antimicrobial Agents and Chemotherapy 2013, 57(1):597-600. AAC.01081-12 [pii]. 10.1128/AAC.01081-12.